|
Anterior Cerebral Circulation Infarction
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
|
Anterior Circulation Brain Infarction
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
|
Brain Infarction, Posterior Circulation
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
|
Venous Infarction, Brain
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
|
Brain Infarction
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Magnetic Resonance Imaging in living mice showed that the in vivo pharmacological or biotechnological knock down of GPR17 markedly prevents brain infarct evolution, suggesting GPR17 as a mediator of neuronal death at this early ischemic stage.
|
18974869 |
2008 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
GPR17 is believed to be a novel target for the development of new therapeutic approaches to human stroke and multiple sclerosis.
|
28223679 |
2017 |
|
Cerebrovascular accident
|
0.040 |
AlteredExpression
|
group |
BEFREE |
GPR17, a receptor transiently expressed on early OPCs, has emerged as a target to implement stroke repair through stimulation of OPC maturation.
|
28594400 |
2017 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
Against this background, we have examined the neuroprotective efficacy of arginine-rich protamine peptides, a cyclic (R12-c) poly-arginine peptide and a R22 poly-arginine peptide, as well as arginine peptides containing tryptophan or other amino acids (phenylalanine, tyrosine, glycine or leucine) in in vitro glutamic acid excitotoxicity and in vivo rat permanent middle cerebral artery occlusion models of stroke.
|
28523591 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Our studies suggest that R-12 displayed potent inhibitory effect on cell growth and colony formation, which is associated with delaying S phase progression by inhibiting DNA synthesis in human hepatoma cancer BEL-7402, SMMC-7721 and ZIP-177 cells.
|
31171403 |
2019 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Our studies suggest that R-12 displayed potent inhibitory effect on cell growth and colony formation, which is associated with delaying S phase progression by inhibiting DNA synthesis in human hepatoma cancer BEL-7402, SMMC-7721 and ZIP-177 cells.
|
31171403 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Mean time from RT to cancer diagnosis 89±70 months (R, 12-276).
|
29757570 |
2018 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Mean time from RT to cancer diagnosis 89±70 months (R, 12-276).
|
29757570 |
2018 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
GPR17 is believed to be a novel target for the development of new therapeutic approaches to human stroke and multiple sclerosis.
|
28223679 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, to univocally define the spatiotemporal changes and final fate of GPR17-expressing OPCs, we induced ischemia by middle cerebral artery occlusion (MCAo) in reporter GPR17iCreER<sup>T2</sup>:CAG-eGreen florescent protein (GFP) mice, in which, upon tamoxifen treatment, cells expressing GPR17 become green and traceable for their entire life.
|
28594400 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine-Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats.
|
28523591 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.030 |
Biomarker
|
disease |
BEFREE |
The rats were divided into eight groups randomly: (1) sham-operated group, (2) ischemia group, (3-5) ischemia-reperfusion (middle cerebral artery occlusion and reperfusion (MCAO/R) 12 h, 48 h, and 7 days) and 0.9% saline groups, (6-8) ischemia-reperfusion (MCAO/R 12 h, 48 h, and 7 days) and Ang-1 groups.
|
21710361 |
2012 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
This ability of R12 highlights its therapeutic potential for treating AD pathology.
|
30916478 |
2019 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Cerebral Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
GPR17 mediates microglial inflammation in the chronic phase of cerebral ischemia and regulates allergic pulmonary inflammation.
|
30036769 |
2018 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
By contrast, accompanying several chromosome losses, germline heterozygous mutations in the tumor suppressor genes, mucin 6, oligomeric mucus/gel-forming (<i>MUC6</i>), and G protein-coupled receptor 17 (<i>GPR17</i>) showed loss of heterozygosity in the two tumors, or in T2, respectively.
|
29725435 |
2018 |